MaxCyte Announces Retirement of Board Member Art Mandell
MaxCyte (MXCT) announced that Board Member Art Mandell will retire effective December 31, 2024, after serving since 2006. Following his departure, the board will consist of nine directors. During Mandell's tenure, MaxCyte achieved significant milestones including its IPO on UK AIM and US Nasdaq, launched the ExPERT™ platform, secured 29 Strategic Platform Licenses with cell and gene therapy companies, and supported the industry's first FDA-approved CRISPR edited non-viral cell therapy. Board Chairman Richard Douglas acknowledged Mandell's contributions in positioning MaxCyte as a leader in cell engineering.
MaxCyte (MXCT) ha annunciato che il membro del consiglio Art Mandell si ritirerà con effetto dal 31 dicembre 2024, dopo aver servito dal 2006. Dopo la sua partenza, il consiglio sarà composto da nove membri. Durante il mandato di Mandell, MaxCyte ha raggiunto traguardi significativi, tra cui il suo IPO su UK AIM e US Nasdaq, il lancio della piattaforma ExPERT™, l'ottenimento di 29 licenze di piattaforma strategica con aziende nel campo della terapia cellulare e genica, e il supporto alla prima terapia cellulare non virale editata con CRISPR approvata dalla FDA. Il presidente del consiglio Richard Douglas ha riconosciuto il contributo di Mandell nel posizionare MaxCyte come leader nell'ingegneria cellulare.
MaxCyte (MXCT) anunció que el miembro de la junta Art Mandell se retirará a partir del 31 de diciembre de 2024, tras haber servido desde 2006. Después de su partida, la junta estará compuesta por nueve directores. Durante el mandato de Mandell, MaxCyte logró hitos significativos, incluyendo su IPO en UK AIM y US Nasdaq, lanzó la plataforma ExPERT™, obtuvo 29 licencias de plataforma estratégica con empresas de terapia celular y génica, y apoyó la primera terapia celular no viral editada con CRISPR aprobada por la FDA. El presidente de la junta, Richard Douglas, reconoció las contribuciones de Mandell en posicionar a MaxCyte como un líder en ingeniería celular.
MaxCyte (MXCT)는 이사회 구성원인 Art Mandell이 2006년부터 재직한 후 2024년 12월 31일부로 은퇴한다고 발표했습니다. 그의 퇴임 후 이사회는 아홉 명의 이사로 구성될 것입니다. Mandell의 재임 기간 동안 MaxCyte는 UK AIM 및 US Nasdaq에서의 IPO, ExPERT™ 플랫폼 출범, 세포 및 유전자 치료 회사와의 29개의 전략적 플랫폼 라이센스 확보, FDA 승인 첫 CRISPR 편집 비바이러스 세포 치료 지원 등 중대한 이정표를 달성했습니다. 이사회 의장 Richard Douglas는 MaxCyte를 세포 공학의 선두주자로 자리매김하는 데 Mandell의 기여를 인정했습니다.
MaxCyte (MXCT) a annoncé que le membre du conseil Art Mandell prendra sa retraite à compter du 31 décembre 2024, après avoir servi depuis 2006. Suite à son départ, le conseil sera composé de neuf membres. Pendant le mandat de Mandell, MaxCyte a atteint des jalons significatifs, notamment son IPO sur UK AIM et US Nasdaq, le lancement de la plateforme ExPERT™, l'obtention de 29 licences de plateforme stratégique avec des entreprises de thérapie cellulaire et génique, et a soutenu la première thérapie cellulaire non virale modifiée par CRISPR approuvée par la FDA. Le président du conseil, Richard Douglas, a reconnu les contributions de Mandell pour positionner MaxCyte en tant que leader dans l'ingénierie cellulaire.
MaxCyte (MXCT) hat bekannt gegeben, dass der Vorstandsmitglied Art Mandell zum 31. Dezember 2024 in den Ruhestand gehen wird, nachdem er seit 2006 im Amt ist. Nach seinem Ausscheiden wird der Vorstand aus neun Direktoren bestehen. Während Mandells Amtszeit erreichte MaxCyte bedeutende Meilensteine, darunter das IPO an der UK AIM und der US Nasdaq, den Start der ExPERT™-Plattform, sicherte 29 strategische Plattformlizenzen mit Unternehmen für Zell- und Gentherapie und unterstützte die erste von der FDA genehmigte CRISPR-bearbeitete nicht-virale Zelltherapie der Branche. Der Vorstandsvorsitzende Richard Douglas würdigte Mandells Beiträge zur Positionierung von MaxCyte als führendes Unternehmen in der Zelltechnik.
- Maintained strong board composition with 9 directors post-retirement
- Demonstrated successful track record with 29 Strategic Platform Licenses
- Achieved significant milestone with first FDA-approved CRISPR non-viral cell therapy support
- Loss of long-term board member with 18 years of company experience
ROCKVILLE, Md., Dec. 22, 2024 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (Nasdaq: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics, today announced that Art Mandell has retired from his position as a member of the Board of Directors of MaxCyte effective December 31, 2024. Mr. Mandell has served on the Board since 2006 and has been an integral part of MaxCyte’s growth and strategic direction. Upon Mr. Mandell’s retirement, MaxCyte will have nine directors.
During Mr. Mandell’s tenure, MaxCyte has achieved significant milestones including its initial public offering on the UK AIM exchange and US Nasdaq Listing, the launch of its flagship ExPERT™ platform, signing 29 Strategic Platform Licenses with cell and gene therapy biotech companies and supporting the industry’s first, FDA-approved, CRISPR edited non-viral cell therapy.
“We are deeply grateful for Art’s exceptional leadership, scientific insights and valuable contributions over the years,” said Richard Douglas, chairman of the Board. “Art’s perspective and guidance have been instrumental in positioning MaxCyte as a leader in cell engineering.”
“It has been a privilege to serve on the Board of MaxCyte,” said Mr. Mandell. “I am proud of all that we have accomplished together, and I am confident in the Company’s bright future providing highly differentiated technology solutions that enable the development of novel cell and gene therapies.”
About MaxCyte
At MaxCyte, we pursue cell engineering excellence to maximize the potential of cells to improve patients’ lives. We have spent more than 25 years honing our expertise by building best-in-class platforms, perfecting the art of the transfection workflow, and venturing beyond today’s processes to innovate tomorrow’s solutions. Our ExPERT™ platform, which is based on our Flow Electroporation® technology, has been designed to support the rapidly expanding cell therapy market and can be utilized across the continuum of the high-growth cell therapy sector, from discovery and development through commercialization of next-generation, cell-based medicines. The ExPERT family of products includes: four instruments, the ATx™, STx™, GTx™ and VLx™; a portfolio of proprietary related processing assemblies or disposables; and software protocols, all supported by a robust worldwide intellectual property portfolio. By providing our partners with the right technology platform, as well as scientific, technical and regulatory support, we aim to guide them on their journey to transform human health. Learn more at maxcyte.com and follow us on X and LinkedIn.
MaxCyte Contacts:
US IR Adviser
Gilmartin Group
David Deuchler, CFA
+1 415-937-5400
ir@maxcyte.com
US Media Relations
Spectrum Science
Jordan Vines
+1 540-629-3137
jvines@spectrumscience.com
Nominated Adviser and Joint Corporate Broker
Panmure Liberum
Emma Earl / Freddy Crossley
Corporate Broking
Rupert Dearden
+44 (0)20 7886 2500
UK IR Adviser
ICR Healthcare
Mary-Jane Elliott
Chris Welsh
+44 (0)203 709 5700
maxcyte@icrhealthcare.com
Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts contained in this press release, including statements regarding our future results of operations or financial condition, business strategy and plans and objectives of management for future operations, are forward-looking statements. These statements are inherently uncertain, and investors are cautioned not to unduly rely on these statements.
Risks and uncertainties related to our business are described in greater detail in Item 1A of our Annual Report on Form 10-K for the year ended December 31, 2023, filed with the Securities and Exchange Commission (“SEC”) on March 12, 2024, as well as in discussions of potential risks, uncertainties, and other important factors in the other filings that we make with the Securities and Exchange Commission from time to time, including in our Form 10-Q for the quarter ended September 30, 2024, filed with the SEC on November 6, 2024. These documents are available through the Investor Menu, Financials section, under “SEC Filings” on the Investors page of our website at http://investors.maxcyte.com. Any forward-looking statements in this press release are based on our current beliefs and opinions on the relevant subject based on information available to us as of the date of such press release, and you should not rely on forward-looking statements as predictions of future events. We undertake no obligation to update any forward-looking statements made in this press release to reflect events or circumstances after the date of this press release or to reflect new information or the occurrence of unanticipated events, except as required by law.
FAQ
When will Art Mandell retire from MaxCyte's (MXCT) Board of Directors?
How many Strategic Platform Licenses has MaxCyte (MXCT) signed during Mandell's tenure?
How many directors will remain on MaxCyte's (MXCT) board after Mandell's retirement?
What major milestones did MaxCyte (MXCT) achieve during Mandell's board tenure?
